The above studies provide new ideas for the remission and treatment of ovarian cancer, by targeting ICOS/ICOSL to inhibit the accumulation of ICOS+ Foxp3+ Tregs in ovarian cancer, thereby eliminating immunosuppression. Here, ICOSLG is linked to ovarian cancer.